Ames, IA 的 非小細胞肺癌 臨床試驗
6 項針對 非小細胞肺癌 的研究正在 Ames(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Accellacare of McFarland, Ames
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Ames 的其他研究
- 前列腺癌7 項研究
- 肺癌7 項研究
- 腎臟癌(腎細胞癌)5 項研究
- 乳癌4 項研究
- 頭頸部鱗狀細胞癌4 項研究
- 膀胱癌4 項研究
- 慢性淋巴性白血病3 項研究
- 下咽癌3 項研究
- 喉癌3 項研究
- 口腔癌3 項研究
- 黑色素瘤3 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。